Are phase 3 HERO results a game-changer for urologists?
"This new therapy could change the landscape for the treatment of advanced prostate cancer," Thrasher writes.
Oral gonadotropin-releasing hormone receptor antagonist shows benefits
Oral GnRH receptor antagonist has “potential to become a new standard for ADT,” a study investigator says.
Is low-intensity surveillance feasible for patients with high-risk NMIBC?
The study compared regimens for patients with high-risk non–muscle invasive bladder cancer.
BPH catheter system shows encouraging outcomes in pilot trial
Significant improvements in BPH-related lower urinary tract symptoms were observed with the system.
Gene-mediated therapy for high-grade NMIBC delivers positive results in trial
72.9% of patients with papillary disease achieved high-grade recurrence-free survival at 3 months after initial treatment.
What has been the telemedicine experience in urology during the COVID-19 pandemic?
3 urologists discuss their experience with telemedicine during the COVID-19 pandemic.
How to fill the gap between retirement, Social Security
Withdrawals from pretax retirement accounts are among the ways to bridge your income, according to Jeff Witz, CFP.
HIFU in focus: An expert's take on high-intensity focused ultrasound
Samuel J. Peretsman, MD, discusses which patients with prostate cancer can be treated with HIFU, contraindications to the treatment, and what expectations patients need to have postoperatively.
Relugolix emerges as "exciting" new treatment in prostate cancer
Dr. Badar M. Mian highlights the safety and efficacy of relugolix, describing the drug as an “exciting new option” for patients with recurrent or advanced prostate cancer.
Testosterone levels show steady decrease among young US men
The decline in total testosterone was observed even among men with normal body mass index.
Rechargeable neuromodulation system safe and efficacious through 1 year
The reduction in urinary urgency incontinence episodes observed was “quite significant,” an investigator said.
It’s time to prepare for upcoming E/M coding changes
The deletion of code 99201 is among the evaluation/management coding changes for 2021.
Photoselective vaporization of the prostate found safe, durably effective
Only 1.5% of patients undergo repeat surgical intervention for BPH recurrence.
